Dr. Antoine Yver is Special Advisor of Clinical Development at Centessa Pharmaceuticals. Previously, Antoine served as Centessa’s Chairman of Development from March 2022 to June 2024 and Chief Medical Officer from May 2021 to February 2022. Antione has more than 30 years of global experience in the pharmaceutical industry and has led the approvals of 11 drugs, including TAGRISSO®, LYNPARZA®, and ENHERTU®. He led the development of TAGRISSO® in 2 years and 7 months from first human dose to US approval and its rapid deployment to all other major regions, which was the fastest ever for an anti-cancer drug. Prior to Centessa, Antoine served as executive vice president and global head, R&D oncology, and chair of the cancer enterprise at Daiichi Sankyo Company, Ltd. Antoine currently serves as an independent director on the board of Sanofi (NASDAQ: SNY) and as an independent board member on the board of Spotlight Therapeutics.
Previously, Antoine was with AstraZeneca, PLC, most recently serving as senior vice president, global medicine head, oncology, and global medicines development China lead.
Earlier, Antoine held various clinical development roles at Schering-Plough/Merck, Johnson & Johnson, Aventis Pharmaceuticals, Inc., Rhône-Poulenc Rorer, Inc., Applied Immune Sciences, Inc., and Chugai-RP.
Antoine is a pediatric oncologist and holds an MD degree from Université Paris-Saclay.
